Leishmaniasis encompasses a spectrum of diseases caused by an obligate intramacrophage protozoa belonging to the genus *Leishmania*. They represent a major public health problem with an annual estimated worldwide incidence of 700 000; a prevalence of 12 million cases; and an estimated mortality of 50 000 patients in 2010 \[[@OFV184C1]\].

Three main forms of American tegumentary leishmaniasis (ATL) occur in Brazil: localized cutaneous, mucocutaneous, and disseminated leishmaniasis (DL). In the state of Sao Paulo, Southeastern Brazil, the localized cutaneous and mucocutaneous forms of ATL are associated with *Leishmania* (*Viannia*) *braziliensis* and *Leishmania amazonensis* \[[@OFV184C2]\].

Disseminated leishmaniasis was first described in 1986, and it has been mainly reported in Northeastern Brazil \[[@OFV184C3]--[@OFV184C7]\]. Disseminated leishmaniasis is characterized by the presence of a great number of pleomorphic cutaneous lesions spanning 2 or more noncontiguous areas of the patient′s body \[[@OFV184C3]--[@OFV184C5]\]. The patients typically report a single initial lesion, usually on the extremities, followed by dissemination that may involve the entire body, sometimes associated with fever and chills \[[@OFV184C4]\]. Although DL accounted for 0.2% of the total number of cases of cutaneous leishmaniosis (CL) in the early 1970s, in 2000 this figure rose to 1.9% \[[@OFV184C5]\], and between 1988 and 2008 its prevalence increased 3-fold and culminated in 2.4% of the total number of cases \[[@OFV184C8]\].

The pathogenesis of DL remains unclear; parasite species, host, and environmental factors may favor parasite dissemination. Disseminated leishmaniasis patients have higher frequency of negative skin test to *Leishmania* antigen \[[@OFV184C4]\] as well as poorer interferon-gamma and tumor necrosis factor-alpha responses than patients with CL \[[@OFV184C3]--[@OFV184C5], [@OFV184C9]\]. Therefore, decreased T-cell response has been hypothesized to play a major role in parasite dissemination, and abnormal chemokine production may be associated with this phenomenon. In the same way, different subpopulations of *L* (*V*) *braziliensis* have been associated with distinct clinical outcomes and caused distinct in vitro reactivity in peripheral blood mononuclear cells of ATL patients. These findings have suggested that certain strains in this complex *L braziliensis* subpopulations may constitute a major risk of DL \[[@OFV184C10]\].

This study describes a series of 18 cases of DL. The first case was diagnosed in 1987 during ongoing outpatient clinic-based surveillance conducted at the University Hospital, Ribeirao Preto Medical School, University of Sao Paulo, Brazil, where DL cases had not been reported before.

SUBJECTS AND METHODS {#s2}
====================

Data Collection {#s2a}
---------------

Patients were attended at the University Hospital of the Ribeirao Preto Medical School, University of Sao Paulo, which is the main reference for the diagnosis and treatment of ATL in the Northeastern region of the state of Sao Paulo, Brazil.

Disseminated Leishmaniasis Diagnosis {#s2b}
------------------------------------

Disseminated leishmaniasis was identified according to a case definition of 10 or more pleomorphic lesions located in 2 or more body parts \[[@OFV184C3]--[@OFV184C5]\]. Laboratorial analyses confirmed case patients by identifying amastigotes forms in skin biopsies or *Leishmania* species in biopsy specimens with molecular methods. Patients with DL were identified between June 1987 and March 2015, by review of the medical charts of all the patients who received a diagnosis of ATL. A standardized entry form was used to extract the demographic, clinical, diagnostic, laboratorial, and treatment information from the medical records.

*Leishmania* Skin Test {#s2c}
----------------------

*Leishmania* skin test (LST) was performed as described previously \[[@OFV184C11]\], and induration equal to or higher than 5 mm, between 48 and 72 hours after the injection, was considered a positive result.

Skin Biopsies {#s2d}
-------------

The diagnosis was defined as leishmaniasis if the parasites were identified on the hematoxylin-eosin or Giemsa-stained sections. *Leishmania* species was determined in smears and/or skin biopsy samples. DNA was extracted from 5 paraffin-embedded skin samples and from 12 cryopreserved skin samples. There was no sample for one of the patients, who was the oldest case, diagnosed in 1987.

Polymerase Chain Reaction {#s2e}
-------------------------

The used primers were based on a sequence of the minicircle kDNA of *Leishmania* sp 5′-(G/C)(G/C)(C/G)CC(A/C)CTAT(A/T)TTACACCCAACCCC-3′ and 5′-GGGGAGGGGCGTTCTGCGAA-3′ (Eurofins, MWG Operon, Huntsville, AL) as described previously \[[@OFV184C2]\]. The reactions were performed in a Mastercycler Pro Thermocycler (Eppendorf, Hamburg, Germany) at the final volume of 23 µL, containing 12.9 µL distilled water, 2 µL 10× buffer (10 µM Tris-HCl \[pH 8.6\], 50 µM KCl, and 1.5 µM MgCl~2~), 2.5 µL dNTPs (2 mM), 0.2 µL of each primer (40 µM), 0.2 µL Taq DNA polymerase (5 U/µL) (Invitrogen, Sao Paulo, Brazil), and 5 µL DNA extract. The amplification cycles included an initial denaturation step of 3 minutes and 30 seconds at 94°C, followed by 35 cycles at 94°C (30 seconds), 60°C (1 minute), 72°C (1 minute), a final extension at 72°C (10 minutes), and incubation at 4°C.

Polymerase Chain Reaction Product Digestion and *Leishmania* Species Identification {#s2f}
-----------------------------------------------------------------------------------

After amplification, *Hae*III and *Bsr*I enzymes (New England Biolabs Inc., Hitchin, England) were used to identify the *Leishmania* species by using the following reaction conditions: 37°C and 1 µL *Hae*III enzyme, 2 µL buffer solution, and 12 µL distilled water, and 5 µL polymerase chain reaction (PCR) product; 65°C and 1 µL *Bsr*I enzyme, 2 µL buffer solution, and 12 µL distilled water, and 5 µL PCR product.

Ethical Approval {#s2g}
----------------

Informed consent was obtained from all the patients. This report was approved by the Local Human Ethics Committee (number 3605/2006) of the University Hospital of the Ribeirao Preto Medical School, University of Sao Paulo, Brazil, in accordance with the ethical standards of the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association.

RESULTS {#s3}
=======

A series of 18 patients---5.4% of ATL patients---with clinically and laboratory-confirmed DL were identified between June 1987 and March 2015 (Table [1](#OFV184TB1){ref-type="table"}). Table 1.Demographic, Clinical, Laboratorial, and Treatment Data of the Patients With Disseminated Leishmaniasis Seen in Southeastern BrazilStateGenderAge at Onset (Years)Year of DiagnosisOccupationEvolution Time (Months)Origin at DiagnosisLSTMucosal InvolvementAmastigotes in Skin SamplesPCR*Leishmania* SubgenusInitial Treatment/Follow UpSPM241987Hiker48Ribeirao Preto CityPositiveNoPresentNo sampleNo sampleGlucantime^2^/CureSPM491988Agriculturist3Pardo RiverNegativeNoPresent+ (P)*Leishmania viannia*Glucantime^2^/CureSPM^a^561988Agriculturist3Santa Cruz da Esperança CityPositiveNoPresent+ (P)*Leishmania viannia*Glucantime^1^/CureMGF331991Agriculturist6Santa Maria de Itabira CityPositiveOralPresent+ (P)*Leishmania viannia*Amphotericin-B^b^/CureMGM501995Agriculturist18Paracatu RiverPositiveNoPresent+*Leishmania viannia*Glucantime^1^/DeathMGM^a^491998Bricklayer1Paracatu RiverNegativeNoPresent+*Leishmania viannia*Glucantime^2^/CureSPM^c^371999Driver1Ribeirao Preto CityNot registeredNasalPresent+ (P)*Leishmania viannia*Amphotericin-B/DeathSPM^a,d^752000Agriculturist8Guatapara CityNegativeNasal and oralPresent+ (P)*Leishmania viannia*Glucantime^2^/DeathMGM472001Welder2Paracatu RiverPositiveNoAbsent+*Leishmania viannia*Glucantime^1^/CureSPM^a^402002Manager Fruit Market3Ribeirao Preto CityNegativeNoAbsent+*Leishmania viannia*Glucantime^2^/CureSPM^a^392008Bricklayer6Espírito Santo do Pinhal CityPositiveOralAbsent+*Leishmania viannia*Glucantime^2^/CureSPM432009Bricklayer8Pardo RiverPositiveNasalPresent+*Leishmania viannia*Glucantime^e^/CureSPM672010Traveling Salesman12Jurucê CityPositiveNasalPresent+*Leishmania viannia*Glucantime^1^/CureSPM382010Agriculturist8Santa Ernestina CityPositiveNoAbsent+*Leishmania viannia*Glucantime^3^/CureSPM372013Driver6Pardo RiverNegativeNoAbsent+*Leishmania viannia*Glucantime^2^/CureSPM582014Bar Owner6Pardo RiverNegativeNoAbsent+*Leishmania viannia*Glucantime^2^/CureSPM432014Machine Operator2Pardo RiverPositiveOralAbsent+*Leishmania viannia*Glucantime^2^/CureSPM582015Electrician7Pardo RiverNegativeNoPresent+*Leishmania viannia*Amphotericin-B/Control[^1][^2][^3][^4][^5][^6][^7]

Demographic, Epidemiological, and Comorbidities Data {#s3a}
----------------------------------------------------

The median age of the patients was 45 years old; the youngest patient was 24 years old, whereas the oldest patient was 75 years old. Seventeen patients were male. Most of the patients were agriculturists (33.3%). No municipalities or farm villages were identified more frequently; however, Pardo River (Sao Paulo state) and Paracatu River (Minas Gerais state) were common places amongst the patients with fishing habit. Twelve patients were smokers; 8 patients were alcoholics. Five patients had diabetes mellitus type 2; just 1 patient had human immunodeficiency virus (HIV) positive serology (no acquired immune deficiency syndrome condition).

Clinical Characteristics {#s3b}
------------------------

The median evolution time was 6 months (minimum, 1 month; maximum, 48 months). An isolated ulcer was the initial clinical manifestation in most cases (55.5%); it emerged mainly in the face and lower extremities (Figure [1](#OFV184F1){ref-type="fig"}). Seven (38.8%) patients had concomitant mucosal involvement; nasal mucosa and/or septum were affected in 4 of these 7 patients, and the same proportion of patients (4 of 7) had oral lesions covering the hard palate. Figure 1.Disseminated leishmaniasis caused by *Leishmania viannia* subgenus. Concomitant mucosal involvement (A) was found in 7 patients. In most cases, an isolated or coalescent ulcers (B), characteristic leishmaniotic, or uncharacteristic ulcer (C) antecede the spreading lesions to cephalic segment, mainly the face, trunk, and limbs, represented by a myriad of acneiform, nodular, or papular lesions, some of them superposed by crusts.

Laboratorial Results {#s3c}
--------------------

Ten (58.8%) of the 17 patients tested positive for LST. The median induration size was 8 mm (minimum, 5 mm; maximum, 14 mm). *Leishmania* skin test had not been registered in the medical chart of 1 patient. The biopsy sections showed infiltration with plasma cells and granulomatous reaction. Amastigotes were identified in 11 (61.1%) skin histological sections. DNA from 17 skin biopsies samples was analyzed by PCR. Amplified *Leishmania* sp was determined for 17 of these samples, which was followed by enzyme digestion to recognize the subgenus *Viannia*.

Treatment Results {#s3d}
-----------------

Fifteen patients were treated initially with pentavalent antimony (Sb^V^; 20 mg/kg per day) for 30 days (1 cycle), and 3 patients were treated with amphotericin B. Patients were evaluated 30 to 60 days after they finished treatment. When they were considered not cured, retreatment was done. Two cycles were necessary to obtain cure for 8 patients. For another one, 3 cycles were necessary. Among patients treated with pentavalent antimony: 1 of them presented secondary effects, and therapy was switched to amphotericin B; and 2 patients died, 1 due a renal acute tubular necrosis and the other due hospital pneumonia. Among the patients treated with amphotericin B (with final doses of 2.5--3.0 g): 1 patient presented impaired liver function, and amphotericin B was switched to pentavalent antimonial; and another one suffered hospital pneumonia (HIV-positive patient), followed by septic shock, and subsequently died.

DISCUSSION {#s4}
==========

The expansion of urban boundaries is accompanied by appearance of diseases that had been previously restricted to rural areas. Southeastern Brazil is not the exception; population growth associated with the constant increase in the agricultural market in these regions have resulted in urban invasion of forest regions \[[@OFV184C12]\]. This scenario presents a new stage of cohabitation with local fauna that was previously confined outside the cities. Nonetheless, outdoor work (such as agriculturist and bricklayer) and outdoor activities (such as fishing) seem to place people at higher risk of acquiring DL due to greater exposure to the *Leishmania*-transmitting mosquito \[[@OFV184C5]\].

Surveillance conducted in the University Hospital of the Ribeirao Preto Medical School, University of Sao Paulo, between 1987 and 2015 showed a total of 335 patients with ATL. The localized cutaneous form corresponded to 70.4% (236 of 335) of the patients (data not published). Disseminated leishmaniasis was diagnosed in 5.4% of ATL cases. The latter percentage represents an important proportion compared with other reported series in which DL corresponded to 2.4% of CL cases \[[@OFV184C8]\]. Although ATL is endemic in Southeastern Brazil, the series of cases reported herein show a considerable number of DL cases. These cases must be monitored and evaluated as a new emerging clinical form of ATL in this region. It is of interest to note that the first DL case in our clinically diagnosed cases was diagnosed in 1987, whereas the first DL case reported in Brazil dates back to 1986 \[[@OFV184C3]\].

According to Turetz et al \[[@OFV184C5]\], old age is a risk factor for DL development---these authors established an odds ratio of 2.57 (95% confidence interval \[CI\], 1.25--5.70) for age over 20 years old. This information is consistent with the age range described in our study (24--75 years old); however, no difference was found when age was categorized in \<20 years old, and ≥20 years old comparing DL to total ATL cases (*P* = .334); in fact, there is no DL patient under 20 years old.

In the present report, DL was more frequently diagnosed among male patients (17 of 18 were males). Our DL cases tend to be more frequently diagnosed in males compared with our total ATL cases, but no significant difference was found (odds ratio \[OR\] = 6.2; 95% CI, 0.82--47.8; *P* = .06). Nevertheless, in a larger series, male gender has been considered as a risk factor for DL (OR = 2.2; 95% CI, 1.03--5.31; *P* = .045) \[[@OFV184C5]\], and another study has also showed this tendency (12 males in 18 DL cases) \[[@OFV184C13]\].

Immune response in DL is able to control parasite growth, and only a few amastigotes remain in the lesion site. As a result of the local inflammatory response, the lesion becomes ulcerated later on \[[@OFV184C4]\]. It is of interest to note that 2 male patients who did not present the amastigote form in the skin biopsy and who tested negative for *Leishmania* sp by PCR analysis, but who fulfilled the clinical definition of DL, were excluded from this analysis. In these 2 cases, *Leishmania* sp etiologic involvement was supported by the epidemiological background, clinical manifestation, suggestive skin histopathological description for *Leishmania* infection (lymphoplasmacytic infiltrate with granuloma formation), and positive therapeutic response to *N*-methyl-glucamine; however, they did not fulfill the inclusion criteria of this report, emphasizing the challenge in DL diagnosis.

In most of our cases, the initial clinical manifestation was the presence of an isolated ulcerated lesion with subsequent development of several cutaneous lesions, including a mixture of acneiform, nodular, and papular lesions as described previously \[[@OFV184C3], [@OFV184C5]\].

Seven (38.8%) patients presented simultaneous mucosal commitment and disseminated skin lesions. Mucosal lesions (MLs) are more frequent in DL patients compared with CL patients \[[@OFV184C5], [@OFV184C14]\]. Normally, MLs occur in 3% of patients with a history of CL and typically appear after several months or years after the initial cutaneous infection \[[@OFV184C1]\].

Pentavalent antimony was the preferred drug used to treat DL. Thirteen patients (81.2%) required 2 or 3 cycles of 30 consecutive days of antimonial treatment to be cured, although a high rate of therapeutic failure is described for DL \[[@OFV184C5]\]. In 1 case, amphotericin B was used with success, and the last diagnosed patient is still under medical control (less than 1-year follow up). Three deaths occurred in the casuistic: 1 was of them due to antimonial side effect (renal acute tubular necrosis), and the others 2 cases were due to pneumonia followed by sepsis or respiratory insufficiency.

In our casuistic, *L viannia* was identified as the subgenus in all DL cases. Considering the epidemiological profile in northeastern Sao Paulo state and the experience in our hospital, this subgenus highly suggests the *L* (*V*) *braziliensis* involvement; notwithstanding, further techniques should be performed to confirm the species. Influence of the parasite genotype on the clinical manifestation of the disease results from a cause-effect relationship. Single-nucleotide polymorphisms and indels associated with DL occur in 6 polymorphic loci in the parasite\'s genome \[[@OFV184C10]\]. Reports on ATL clusters in Northeastern Brazil support the idea that the clinical manifestation of DL is related with a particular strain of the parasite \[[@OFV184C7], [@OFV184C10], [@OFV184C15]\]. The genetic background of the *Leishmania* parasite reported here should be determined for the detection of strains.

CONCLUSIONS {#s5}
===========

The present case series has reported on a detailed epidemiological, clinical, and laboratorial profile of an emerging form of ATL. Considering the alarming growing incidence of DL cases, clinicians must be aware of this emerging form of ATL. The challenges in this field include the difficulty to perform differential diagnosis amongst neglected dermatosis and to manage the disease.
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[^1]: Abbreviations: HIV, human immunodeficiency virus; LST, *Leishmania* skin test; MG, Minas Gerais; (P), paraffin-embedded tissue; PCR, polymerase chain reaction; SP, Sao Paulo.

[^2]: ^a^ Patient with diabetes mellitus type 2.

[^3]: ^b^ Switched to glucantime^2^ due impairment liver function.

[^4]: ^c^ Patient with HIV positive serology.

[^5]: ^d^ Patient with chronic pulmonary obstructive disease.

[^6]: ^e^ Switched to amphotericin B due phlebitis and tremors.

[^7]: ^1,2,3^ Number of cycles of 30 consecutive days with interval of 30 to 60 days prescribed to be cured.
